Menu Close

EPG Wealth Management LLC Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)

EPG Wealth Management LLC increased its position in Johnson & Johnson (NYSE:JNJGet Rating) by 16.7% during the 1st quarter, Holdings Channel.com reports. The firm owned 7,272 shares of the company’s stock after purchasing an additional 1,042 shares during the period. EPG Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,289,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in Johnson & Johnson by 2.6% in the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock worth $34,217,654,000 after purchasing an additional 4,982,885 shares during the period. State Street Corp boosted its holdings in Johnson & Johnson by 1.8% in the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after acquiring an additional 2,492,359 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Johnson & Johnson by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock worth $7,576,867,000 after acquiring an additional 1,084,834 shares in the last quarter. Norges Bank bought a new stake in Johnson & Johnson in the fourth quarter worth $4,172,929,000. Finally, Legal & General Group Plc boosted its holdings in Johnson & Johnson by 5.8% in the fourth quarter. Legal & General Group Plc now owns 17,420,146 shares of the company’s stock worth $2,980,062,000 after acquiring an additional 948,306 shares in the last quarter. 68.78% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 0.9 %

JNJ stock opened at $166.13 on Wednesday. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The business’s 50-day moving average is $173.32 and its two-hundred day moving average is $174.48. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.17 and a current ratio of 1.42. The company has a market cap of $436.79 billion, a price-to-earnings ratio of 24.18, a P/E/G ratio of 3.22 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. During the same quarter in the prior year, the company earned $2.48 earnings per share. Johnson & Johnson’s revenue was up 3.0% on a year-over-year basis. As a group, analysts forecast that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.72%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s payout ratio is 65.79%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. Company insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several analyst reports. SVB Leerink dropped their target price on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. UBS Group dropped their target price on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Morgan Stanley upped their price target on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a report on Friday, July 8th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Finally, Citigroup lowered their price target on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.